Dietary Supplementation of Lactogyn in Women With Bacterial Vaginosis

Vesale Pharmaceutica166 enrolled

Overview

The objective of the study is to determine clinical efficacy of Lactogyn (Lactobacillus Crispatus, L. brevis, L.acidophilus) in prevention of recurrent BV

According to classification, this is a phase 2 randomized parallel group prospective controlled dietary study to evaluate efficacy of a dietary supplement, a combination of L. crispatus LMG S-29995, L. brevis, and L. acidophilus in women aged from 18 through 45 years suffering from rBV. The 2 phase of the study has been ascribed as there is no evidence that oral capsules with L. crispatus LMG S-29995, L. brevis, and L. acidophilus have a potential efficacy in rBV. Qualifying women received a combination of the three probiotic strains with a half daily recommended dose of vitamin C or just vitamin C without probiotics, a control supplementation, via oral route of administration for up to 120 days. During the intake of active or control formulations, participants kept a structured 120-DSD, where they recorded test capsules intake, screen for symptoms of bacterial vaginosis, and food intolerance events. Based on repeat physical examination with application of Amsel and Nugent criteria the main conclusions over the efficacy of probiotic strains were made.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

TRIPLE

Enrollment

166

Conditions

Bacterial Vaginosis

Interventions

LactogynDIETARY_SUPPLEMENT

capsules

PlaceboDIETARY_SUPPLEMENT

capsules

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 45 Years

Medical Language ↔ Plain English

Inclusion criteria 1. Informed consent form signed; 2. Age: 18-45 years; 3. Able to swallow capsules; 4. Recent symptomatic BV successfully treated with metronidazole tablets in a dose of 500 mg 2 times daily for 7 days; 5. Less than 48 hours after treatment of acute BV defined as three out of four Amsel criteria; 6. Willing to communicate intimate history for the study purposes; 7. Consent not to use spermicides for 4 months after starting TDC; 8. Stated availability throughout the study period and a mobile phone. Exclusion criteria 1. Post-menopausal; 2. Pregnancy or high risk of; 3. Breast feeding; 4. Currently active STD as determined by history, physical examination, and laboratory tests; 5. Diabetes mellitus; 6. Inflammatory bowel disease; 7. Alcohol or drug addiction as guessed by investigator; 8. Absence of refrigerator; 9. Known moderate to severe disease of any systems; 10. Difficulty to comprehend study requirements as judged by physician; 11. Any erosions, herpes like lesions, cervicitis during vaginal examination; 12. Treatment of BV with other than metronidazole antibiotic; 13. Use of any investigational drug within the previous 30 days; 14. Use of drugs that suppress the immune system.

Locations (1)

Sergiy V. Gerasymov, MD, PhD

Lviv, Ukraine

Outcomes

Primary Outcomes

Percent change in recurrence of BV during Lactogyn supplementation

Percent change in recurrence of BV during the 4 months of dietary supplementation

Time frame: 4 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.